Evidence map›Paper›PMID 37939112›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer.

Noah Earland, Nicholas P Semenkovich, Ricardo J Ramirez, Sophie P Gerndt, Peter K Harris, Zhuosheng Gu, Andrew I Hearn, Matthew Inkman, Jeffrey J Szymanski, Damion Whitfield and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  4. The Canadian Breast Cancer Symposium 2025: Meeting Report.Current oncology (Toronto, Ont.) · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Noah EarlandDivision of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-0170-407X
Nicholas P SemenkovichDivision of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-5266-6734
Ricardo J RamirezDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-6483-5109
Sophie P GerndtDivision of Otolaryngology-Head and Neck Surgery, Allegheny Health Network, Pittsburgh, Pennsylvania.ORCID 0000-0001-9918-453X
Peter K HarrisDivision of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-1557-1722
Zhuosheng GuDroplet Biosciences, Inc., Cambridge, Massachusetts.ORCID 0009-0007-6395-2665
Andrew I HearnDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-9684-7622
Matthew InkmanDivision of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-5490-2374
Jeffrey J SzymanskiDivision of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-8005-701X
Damion WhitfieldDroplet Biosciences, Inc., Cambridge, Massachusetts.ORCID 0009-0001-9708-0582
Benjamin M WahleDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-8806-2190
Zhongping XuDepartment of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0009-0000-2307-5580
Kevin ChenDivision of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-3868-8456
Irfan AlahiDivision of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Gabris NiDivision of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0009-0008-3901-6508
Andrew ChenDivision of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0009-0008-9742-127X
Wendy WincklerDroplet Biosciences, Inc., Cambridge, Massachusetts.ORCID 0009-0008-9893-9652
Jin ZhangDivision of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-9117-2793
Aadel A Chaudhuri *Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-3115-3061
Jose P Zevallos *Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0009-0003-2442-6014
Washington University in St. Louis · USAxios Biosciences (United States) · USAllegheny Health Network · USUniversity of Pittsburgh Medical Center · USUPMC Hillman Cancer Center · US

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)U2CCA252981 · NCI · WASHINGTON UNIVERSITY · PI GRAHAM A. COLDITZ, Li Ding · 2021 to 2026
$18.5M
DIABETES &RELATED METABOLIC DISEASEST32DK007120 · NIDDK · WASHINGTON UNIVERSITY · PI MARCO COLONNA, Maria Sara Remedi · 1986 to 2026
$15.7M
DEVELOPMENT OF CLINICIAN/RESEARCHERS IN ACADEMIC ENTT32DC000022 · NIDCD · WASHINGTON UNIVERSITY · PI PICCIRILLO, JAY F. · 1989 to 2022
$5.6M
Development of a Four-Class, Molecular Subtyping Diagnostic for HPV-negative Head and Neck CancerR01CA211939 · NCI · WASHINGTON UNIVERSITY · PI HAYES, DAVID N, ZEVALLOS, JOSE P. · 2017 to 2021
$2.3M
Integrating multi-omics, imaging, and longitudinal data to predict radiation response in cervical cancerR01CA276955 · NCI · WASHINGTON UNIVERSITY · PI Jin Zhang · 2023 to 2026
$2.1M
HPV genomic structure in cervical cancer radiation response and recurrence detectionR37CA279596 · NCI · WASHINGTON UNIVERSITY · PI Jin Zhang · 2023 to 2026
$2.0M
A Novel Postoperative Prognostic Liquid Biopsy: Tumor-Associated cfDNA and Leukocyte Analysis in Oropharyngeal Cancer Surgical Drain FluidF30CA281071 · NCI · WASHINGTON UNIVERSITY · PI EARLAND, NOAH JACKSON · 2023 to 2025
$123k
NCATS NIH HHS UL1 TR002345NCI NIH HHS F30 CA281071NCI NIH HHS R01 CA211939NCI NIH HHS R01 CA276955NCI NIH HHS R37 CA279596NCI NIH HHS U2C CA252981NIDCD NIH HHS T32 DC000022NIDDK NIH HHS T32 DK007120
6 · The paper itself

Abstract

purposeOur goal was to demonstrate that lymphatic drainage fluid (lymph) has improved sensitivity in quantifying postoperative minimal residual disease (MRD) in locally advanced human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) compared with plasma, and leverage this novel biofluid for patient risk stratification. EXPERIMENTAL

designWe prospectively collected lymph samples from neck drains of 106 patients with HPV (+) OPSCC, along with 67 matched plasma samples, 24 hours after surgery. PCR and next-generation sequencing were used to quantify cancer-associated cell-free HPV (cf-HPV) and tumor-informed variants in lymph and plasma. Next, lymph cf-HPV and variants were compared with TNM stage, extranodal extension (ENE), and composite definitions of high-risk pathology. We then created a machine learning model, informed by lymph MRD and clinicopathologic features, to compare with progression-free survival (PFS).

resultsPostoperative lymph was enriched with cf-HPV compared with plasma (P < 0.0001) and correlated with pN2 stage (P = 0.003), ENE (P < 0.0001), and trial-defined pathologic risk criteria (mean AUC = 0.78). In addition, the lymph mutation number and variant allele frequency were higher in pN2 ENE (+) necks than in pN1 ENE (+) (P = 0.03, P = 0.02) or pN0-N1 ENE (-) (P = 0.04, P = 0.03, respectively). The lymph MRD-informed risk model demonstrated inferior PFS in high-risk patients (AUC = 0.96, P < 0.0001).

conclusionsVariant and cf-HPV quantification, performed in 24-hour postoperative lymph samples, reflects single- and multifeature high-risk pathologic criteria. Incorporating lymphatic MRD and clinicopathologic feature analysis can stratify PFS early after surgery in patients with HPV (+) head and neck cancer. See related commentary by Shannon and Iyer, p. 1223.

Indexed as

Head and Neck NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsHuman Papillomavirus VirusesHumansNeoplasm, ResidualNeoplasm StagingPrognosisRetrospective StudiesSquamous Cell Carcinoma of Head and Neck

Identifiers

PMID37939112
PMCPMC10982646
OpenAlexW4388487613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.